摘要：目的：探讨培美曲塞联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法： 经病理学或细胞学确诊的晚期NSCLC患者31例，其中男性20例，女性11例，中位年龄62岁，KPS评分≥70分。培美曲塞500mg/m2第一天静脉滴注联合顺铂 25mg/m2 第1-3天静脉滴注，每三周为一个周期。使用2周期以上后评价疗效及不良反应。结果： 31例患者均可评价疗效，CR1例，PR3例，SD18例，PD9例，疾病控制率71%，1年生存率32%，中位疾病进展时间4.0月。主要不良反应为白细胞、血小板下降及胃肠道反应。结论： 培美曲塞联合顺铂治疗晚期非小细胞肺癌疗效明确，患者耐受性好，不良反应轻。

    关键词： 培美曲塞 非小细胞肺癌 顺铂

    Abstract：ObjectThisstudyexplorethecurativeeffect andadversereaction of pemetrexedcombined with cisplatinin advancednon-smallcelllungcancer(NSCLC).Methods31casesofadvancedNSCLCpatients confirmed bypathologyorcytology were selected and divided into 20casesofmenand11 casesof women.The medianagewas 62years old and KPSscorewas greater than or equal to 70points.Pemetrexed was used onthefirstday with dose of 500mg/m2 when cisplatinused for 1-3days with dose 25mg/m2 .Both were administered through intravenousdrip way every 3 weeks for 2 cycles to evaluate thecurativeeffect andadversereaction of the therapy .ResultsAll the 31 cases were available for objective response and there are CR 1 case ......